Does the media refer more to KYTX or ZLAB?

In the previous week, Kyverna Therapeutics had 5 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 2 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.62 beat Kyverna Therapeutics' score of 0.33 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BHC or KYTX?

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Bausch Health Cos. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 3 mentions for Bausch Health Cos. Kyverna Therapeutics' average media sentiment score of 0.33 beat Bausch Health Cos' score of 0.16 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, KYTX or HCM?

HUTCHMED has higher revenue and earnings than Kyverna Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A HUTCHMED $548.51M 3.55 $456.91M N/A N/A

Is KYTX or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% HUTCHMED N/A N/A N/A

Does the media refer more to KYTX or HCM?

In the previous week, Kyverna Therapeutics had 6 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.31 beat Kyverna Therapeutics' score of 0.33 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate KYTX or MESO?

Kyverna Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 277.36%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Mesoblast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is KYTX or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Mesoblast N/A N/A N/A

Does the media refer more to KYTX or MESO?

In the previous week, Kyverna Therapeutics had 6 more articles in the media than Mesoblast. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 1 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Kyverna Therapeutics' score of 0.33 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, KYTX or TYRA?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A Tyra Biosciences N/A N/A -$119.95M -$2.18 N/A

Is KYTX or TYRA more profitable?

Tyra Biosciences' return on equity of -42.66% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Tyra Biosciences N/A -42.66% -39.79%

Does the media refer more to KYTX or TYRA?

In the previous week, Kyverna Therapeutics had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Kyverna Therapeutics' score of 0.33 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kyverna Therapeutics (KYTX) Competitors

$7.95 +0.13 (+1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$7.96 +0.01 (+0.13%)

As of 06:51 PM Eastern

Compare

KYTX vs. ZLAB, BHC, HCM, MESO, and TYRA

Should you buy Kyverna Therapeutics stock or one of its competitors? MarketBeat compares Kyverna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kyverna Therapeutics include Zai Lab (ZLAB), Bausch Health Cos (BHC), HUTCHMED (HCM), Mesoblast (MESO), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry.

How does Kyverna Therapeutics compare to Zai Lab?

Kyverna Therapeutics (NASDAQ:KYTX) and Zai Lab (NASDAQ:ZLAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kyverna Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 277.36%. Zai Lab has a consensus price target of $45.83, suggesting a potential upside of 164.32%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kyverna Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

Kyverna Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

In the previous week, Kyverna Therapeutics had 5 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 2 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.62 beat Kyverna Therapeutics' score of 0.33 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Zai Lab	$453.28M	4.34	-$175.54M	-$1.62	N/A

Kyverna Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Zai Lab	-39.29%	-24.32%	-15.52%

Summary

Kyverna Therapeutics beats Zai Lab on 8 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

In the previous week, Kyverna Therapeutics had 4 more articles in the media than Bausch Health Cos. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 3 mentions for Bausch Health Cos. Kyverna Therapeutics' average media sentiment score of 0.33 beat Bausch Health Cos' score of 0.16 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch Health Cos has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

Bausch Health Cos presently has a consensus price target of $8.00, indicating a potential upside of 52.53%. Kyverna Therapeutics has a consensus price target of $30.00, indicating a potential upside of 277.36%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Bausch Health Cos has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

Kyverna Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Kyverna Therapeutics' return on equity of -81.88% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Kyverna Therapeutics beats Bausch Health Cos on 8 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to HUTCHMED?

Kyverna Therapeutics (NASDAQ:KYTX) and HUTCHMED (NASDAQ:HCM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Kyverna Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 277.36%. HUTCHMED has a consensus price target of $16.80, suggesting a potential upside of 50.40%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Kyverna Therapeutics had 6 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.31 beat Kyverna Therapeutics' score of 0.33 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

HUTCHMED's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
HUTCHMED	N/A	N/A	N/A

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

HUTCHMED has higher revenue and earnings than Kyverna Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
HUTCHMED	$548.51M	3.55	$456.91M	N/A	N/A

Summary

Kyverna Therapeutics beats HUTCHMED on 7 of the 13 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Mesoblast?

Kyverna Therapeutics (NASDAQ:KYTX) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Kyverna Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 277.36%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Mesoblast's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Mesoblast	N/A	N/A	N/A

Kyverna Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market.

In the previous week, Kyverna Therapeutics had 6 more articles in the media than Mesoblast. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 1 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Kyverna Therapeutics' score of 0.33 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Mesoblast has higher revenue and earnings than Kyverna Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Mesoblast	$65.38M	29.56	-$102.14M	-$0.54	N/A

Summary

Mesoblast beats Kyverna Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Tyra Biosciences?

Kyverna Therapeutics (NASDAQ:KYTX) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, Kyverna Therapeutics had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.93 beat Kyverna Therapeutics' score of 0.33 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 277.36%. Tyra Biosciences has a consensus target price of $46.50, suggesting a potential upside of 71.08%. Given Kyverna Therapeutics' higher probable upside, equities research analysts clearly believe Kyverna Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Kyverna Therapeutics has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Tyra Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tyra Biosciences' return on equity of -42.66% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Tyra Biosciences	N/A	-42.66%	-39.79%

Summary

Tyra Biosciences beats Kyverna Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYTX vs. The Competition

Export

Metric	Kyverna Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$475.42M	$3.28B	$6.30B	$12.43B
Dividend Yield	N/A	2.36%	2.69%	5.33%
P/E Ratio	-2.42	18.46	24.03	24.35
Price / Sales	N/A	317.64	518.85	114.60
Price / Cash	N/A	111.03	41.39	55.53
Price / Book	2.06	6.77	9.98	6.72
Net Income	-$161.31M	$24.09M	$3.56B	$337.03M
7 Day Performance	-8.09%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	178.95%	48.90%	28.76%	33.98%

Kyverna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYTX Kyverna Therapeutics	2.3157 of 5 stars	$7.95 +1.7%	$30.00 +277.4%	+180.3%	$475.42M	N/A	N/A	96	News Coverage Analyst Forecast
ZLAB Zai Lab	3.2205 of 5 stars	$17.16 +0.4%	$45.83 +167.1%	-44.8%	$2.01B	$460.16M	N/A	1,784
BHC Bausch Health Cos	3.12 of 5 stars	$5.03 -5.5%	$8.00 +59.2%	+8.2%	$2.00B	$10.53B	N/A	20,300	Gap Up
HCM HUTCHMED	3.9345 of 5 stars	$11.55 +1.3%	$16.80 +45.5%	-23.1%	$2.00B	$548.51M	N/A	1,796	Positive News High Trading Volume
MESO Mesoblast	1.1061 of 5 stars	$14.52 -2.3%	N/A	+37.6%	$1.99B	$65.38M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYTX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. ZLAB, BHC, HCM, MESO, and TYRA

How does Kyverna Therapeutics compare to Zai Lab?

Summary

How does Kyverna Therapeutics compare to Bausch Health Cos?

Summary

How does Kyverna Therapeutics compare to HUTCHMED?

Summary

How does Kyverna Therapeutics compare to Mesoblast?

Summary

How does Kyverna Therapeutics compare to Tyra Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. ZLAB, BHC, HCM, MESO, and TYRA

How does Kyverna Therapeutics compare to Zai Lab?

Do insiders & institutionals have more ownership in KYTX or ZLAB?

Do analysts recommend KYTX or ZLAB?

Which has more volatility and risk, KYTX or ZLAB?

Does the media refer more to KYTX or ZLAB?

Which has preferable earnings & valuation, KYTX or ZLAB?

Is KYTX or ZLAB more profitable?

Summary

How does Kyverna Therapeutics compare to Bausch Health Cos?

Does the media refer more to BHC or KYTX?

Which has more volatility and risk, BHC or KYTX?

Do analysts rate BHC or KYTX?

Which has stronger earnings and valuation, BHC or KYTX?

Is BHC or KYTX more profitable?

Do insiders and institutionals have more ownership in BHC or KYTX?

Summary

How does Kyverna Therapeutics compare to HUTCHMED?

Do analysts recommend KYTX or HCM?

Does the media refer more to KYTX or HCM?

Which has more risk and volatility, KYTX or HCM?

Is KYTX or HCM more profitable?

Do institutionals & insiders have more ownership in KYTX or HCM?

Which has higher earnings and valuation, KYTX or HCM?

Summary

How does Kyverna Therapeutics compare to Mesoblast?

Do analysts rate KYTX or MESO?

Is KYTX or MESO more profitable?

Which has more risk and volatility, KYTX or MESO?

Does the media refer more to KYTX or MESO?

Do institutionals and insiders have more ownership in KYTX or MESO?

Which has higher valuation & earnings, KYTX or MESO?

Summary

How does Kyverna Therapeutics compare to Tyra Biosciences?

Does the media refer more to KYTX or TYRA?

Do analysts rate KYTX or TYRA?

Which has more volatility and risk, KYTX or TYRA?

Which has preferable earnings and valuation, KYTX or TYRA?

Do insiders and institutionals have more ownership in KYTX or TYRA?

Is KYTX or TYRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools